Scott Got­tlieb will push to pub­lish CRLs; Marathon's demise of­fers the in­dus­try a cau­tion­ary tale

End­points News as­sess­es the big bio­phar­ma sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Scott Got­tlieb did the right thing of­fer­ing to pub­lish those CRLs

Dur­ing Scott Got­tlieb’s last round of writ­ten an­swers to the Sen­ate com­mit­tee re­view­ing his nom­i­na­tion as FDA com­mis­sion­er, I was pleased to see him vol­un­tar­i­ly pro­pose that the agency start pub­lish­ing com­plete re­sponse let­ters. Got­tlieb has done that be­fore, but so far we haven’t seen a recom­mit af­ter his nom­i­na­tion.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE